TABLE 3. Unique DLTs observed in oncology pediatric trials in response to written requests initiated since 2001.

|  |  |
| --- | --- |
| **Drug Name** | **Unique DLTs in Pediatric** |
| Irinotecan hcl (Camptosar) (Camptosar) | Dehydration associated with severe hypokalemia and hyponatremia |
| Sunitinib malate (Sutent) (Sutent) | Dose-limiting cardiotoxicity |
| Nilotinib (Tasigna) (Tasigna) | Growth retardation |